Phase 2 Breast Cancer Trial, Recruiting NCT06728579 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06728579
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older who are proficient in English
  • People with a history of stage I, II, or III breast cancer
  • People who currently show no signs of active cancer based on clinical examination and medical history
  • People who have been taking a specific type of hormone therapy called an aromatase inhibitor (anastrozole, letrozole, or exemestane) for at least 28 days before joining, with a plan to continue for at least another 12 months
  • People whose worst joint pain in the past week was rated at least 4 out of 10 on a pain scale
  • People who experienced pain on at least 15 days out of the 30 days before joining the trial
  • People whose joint pain has been present for at least one month
  • People whose joint pain is believed to be caused by their hormone therapy
  • People who are willing to follow all study procedures, including being randomly assigned to one of two group therapy programs (either Mindfulness-Oriented Recovery Enhancement or Supportive Group Psychotherapy)
  • People who are able to attend video call sessions from a quiet and private location

Who may not be able to join:

  • People with stage IV (metastatic) breast cancer
  • People who completed chemotherapy, surgery, or radiation therapy less than 4 weeks before enrolling
  • People whose joint pain is linked to inflammatory conditions such as rheumatoid arthritis, gout, or pseudogout
  • People who have had surgery or an injection in the affected joint(s) within the last month, or who have one planned within the next six months
  • People identified as having active suicidal thoughts or psychosis, as assessed through a specific psychiatric screening interview (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jun Mao, MD, MSCE, Memorial Sloan Kettering Cancer Center

Phone: 646-608-8553

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
6 December 2024
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pain Interference

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov